Therapy with 188Re-Labeled Radiopharmaceuticals: An Overview of Promising Results from Initial Clinical Trials

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 5, 2003, Pages 707-717

  Jeong, Jae Min ^a   Chung, June Key ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

188Re; Radionuclide therapy; Rhenium

Indexed keywords

ALENDRONATE RE 188; ETIDRONIC ACID RE 188; LEXIDRONAM SAMARIUM RE 188; MERTIATIDE RE 188; MICROSPHERE; MONOCLONAL ANTIBODY; N HEXYLDIAMINEDITHIOL LIPIODOL RE 188; P 2045; P 2045 RE 188; PENTETIC ACID RE 188; PEPTIDE; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; TUNGSTEN; UNCLASSIFIED DRUG; VAPREOTIDE; IODINATED POPPYSEED OIL; RHENIUM;

BONE PAIN; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DRUG LABELING; DRUG RESEARCH; DRUG SPECIFICITY; EFFUSION; HUMAN; ISOTOPE LABELING; LIVER CANCER; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; BONE DISEASE; CHEMISTRY; CORONARY BLOOD VESSEL; IMMUNOLOGY; PAIN; RADIATION EXPOSURE;

ANTIBODIES, MONOCLONAL; BONE DISEASES; CLINICAL TRIALS; CORONARY VESSELS; IODIZED OIL; PAIN; RADIOPHARMACEUTICALS; RHENIUM;

EID: 0242665531     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803770418256     Document Type: Review

References (76)

1. Callahan AP, Rice DE, Knapp FF Jr. Rhenium-188 for therapeutic applications from an alumina based tungsten-188/rhenium-188 radionuclide generator. Nuc-Compact-Eur/Amer Commun Nucl Med 1989;20:3.
2. Callahan AP, Rice DE, McPherson DW, et al. The use of alumina "SepPak" as a simple method for the removal and determination of tungsten-188 breakthrough from tungsten-188/rhenium-188 generators. Appl Radiat Isot 1992;43:801.
3. 188Re generators. Appl Radiat Isot 1994;45:1123.
4. Knapp FF Jr, Mirzadeh S, Beets AL, et al. Curie-scale tungsten-188/rhenium-188 generators for routine clinical applications. In: Technetium and Rhenium Chemistry and Nuclear Medicine. Proceedings of the Symposium held in Bressanone, Italy, September 12-14, 1994. Nicolini M, Bandoli G, Mazzi U, eds., Padova, Italy: SG Editorial, 1995.
5. Chang YS, Jeong JM, Lee DS, et al. Quality control of tungsten-188/rhenium-188 generator. Korean J Nucl Med 1998;32:425.
6. 188Re generators. Appl Radiat Isot 1996;47:23.
7. 188/rhenium-188 generator to provide high levels of carrier-free rhenium-188 for radioimmunotherapy (RAIT). In: Nuclear Medicine in Research and Practice. Stutgart, Germany: Schattauer Verlag, 1992:183.
8. Waksman R, Serruys PW. Handbook of Vascular Brachytherapy. London: Martin Dunitz, 1998.
9. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697.
10. Mazur W, Ali MN, Khan MM, et al. High dose rate intracoronary radiation for inhibition of neointimal formation in the stented and balloon-injured porcine models of restenosis: angiographic, morphometric, and histopathologic analyses. Int J Radiat Oncol Biol Phys 1996;36:777-788.
11. Bole PV, Hintz G, Chander P, et al. Bilateral carotid aceurysms secondary to radiation therapy. Ann Surg 1975;181:888.
12. Weinberger J, Amols H, Ennis RD, et al. Intracoronary irradiation: Dose response for the prevention of restenosis in swine. Int J Radiat Oncol Biol Phys 1996;36:767.
13. Amols HI, Zaider M, Weinberger J, et al. Dosimetric consideration for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries. Int J Radiat Oncol Biol Phys 1996;36:913.
14. Knapp FF Jr, Guhlke S, Beets AL, et al. Rhenium-188-attractive properties for intravascular brachytherapy for inhibition of coronary artery restenosis after PTCA [abstr.]. J Nucl Cardiol 1997;4:S118.
15. Weinberger J, Amols HL, Schiff PB, et al. Initial results of the CURE safety trial: Coronary brachytherapy with radioactive-liquid-filled balloons [abstr.]. J Am Coll Cardiol 1999;33:94A.
16. Giedd KN, Amols H, Marbos C, et al. Effectiveness of a beta-emitting liquid-filled balloon to prevent restenosis [abstr.]. Circulation 1997;96:I.
17. Lee J, Lee DS, Kim YJ, et al. Labeling and biodistribution of Re-188-DTPA (diethylenetriaminepentaacetic acid). Korean J Nucl Med 1997;31:427.
18. Lee J, Lee DS, Kim KM, et al. Dosimetry of rhenium-188 diethylene triamine pentaacetic acid for endovascular intraballoon brachytherapy after coronary angioplasty. Eur J Nucl Med 2000;27:76.
19. 188Re-MAG3 for intracoronary radiation therapy. Appl Radiat Isot 2001;54:419.
20. Teirstein P. β-radiation to reduce restenosis. Too little, too soon? Circulation 1997;95:1095.
21. Knapp FF Jr, Beets AL, Guhlke S, et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res 1997;17:1738.
22. 188Re generator. J Nucl Med 2000;41:1271.
23. Mushtaq A. Preparation of high specific-volume solutions of technetium-99m and rhenium-188. Appl Radiat Isot 2003;58:309.
24. 188Re-filled balloon: Six-month results from a clinical safety and feasibility study. Circulation 2000;101:2355.
25. 188Re-filled balloon system to reduce restenosis after coronary intervention [abstr.]. J Nucl Med 2000;41:128.
26. Habert JC, Robertson JS, Held KD. Nuclear Medicine Therapy. New York: Thieme Medical Publishers; 1987:169.
27. Wang S-J, Lin W-Y, Hsieh B-T, et al. Rhenium-188 sulfur colloid as a radiation synovectomy agent. Eur J Nucl Med 1995;22:505.
28. Kim YJ, Jeong JM, Chang YS, et al. Preparation and biodistribution of Re-188 sulfur colloid. Korean J Nucl Med 1998;32:298.
29. Grillenberger KG, Glatz S, Reske SN. Rhenium-188 labeled hydroxyapatite and rhenium-188 sulfur colloid. Nukleamedizine 1997;36:71.
30. Jeong JM, Lee YJ, Kim YJ, et al. Preparation of rhenium-188-tin colloid as a radiation synovectomy agent and comparison with rhenium-188-sulfur colloid. Appl Radiat Isot 2000;52:851.
31. 188Re-tin colloid as a new therapeutic agent for rheumatoid arthritis. Nucl Med Comm 2003;24:689.
32. 188Re) glass microspheres. Int J Radiat Oncol Biol Phys 1999;44:189.
33. Wang SJ, Lin WY, Chen MN, et al. Rhenium-188 microspheres: A new radiation synovectomy agent. Nucl Med Commun 1998;19:427.
34. Wang S-J, Lin W-Y, Chen M-N, et al. Histologic study of effects of radiation synovectomy with rhenium-188 microsphere. Nucl Med Biol 2001;28:727.
35. Wunderlich G, Pinkert J, Andreeff M, et al. Preparation and biodistribution of rhenium-188 labeled albumin microsphere B 20: A promising new agent for radiotherapy. Appl Radiat Isot 2000;52:63.
36. 188Re-labeled paper for treating of skin cancer. Appl Radiat Isot 2003;58:551.
37. Park CH, Suh JH, Yoo HS. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Clin Nucl Med 1986;11:514.
38. Yoo HS, Suh JH, Lee JT, et al. Therapeutic feasibility study and clinical trial of intrahepatic I-131-lipiodol on patients with hepatocellular carcinoma. Korean J Nucl Med 1986;20:61.
39. 188Re for hepatic tumor therapy. Appl Radiat Isot 1996;47:267.
40. Wang S-J, Lin W-J, Chen M-N, et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumors. Eur J Nucl Med 1996;23:13.
41. Kim YJ, Jeong JM, Kim SK, et al. Rhenium-188-sulfur colloid suspended in lipiodol: A capillary-blocking radiopharmaceutical for targeting liver cancer [abstr.] J Nucl Med 1998;39:235P.
42. 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28:197.
43. Lever SZ, Burns HD, Kervitsky TM, et al. Design, preparation, and biodistribution of a technetium-99m triaminedithiol complex to assess regional cerebral blood flow. J Nucl Med 1985;26:1287.
44. 188Re-TDD-lipiodol in treatment of inoperable primary hepatocellular carcinoma-A case report. Ann Acad Med Singapore 2001;30:542.
45. 188Re labeled long chain alkyl TDD for therapy of liver cancer. Nucl Med Commun 2002;23:237.
46. 188Re-HDD-lipiodol as a new therapeutic agent for liver cancer: A preclinical study in liver cancer-xenografted rabbits [abstr.]. J Nucl Med 2002;43:42P.
47. Sundram FX, Jeong JM, Zanzonico P, et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-center phase 1 study. World J Nucl Med 2002;1:5.
48. Low-Beer BVA, Lawrence JH, Stone RS. The therapeutic use of artificially produced radioactive substances. Radiology 1942;39:573.
49. Firusian N, Mellin P, Schimidt CG. Results of 89-strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: A preliminary report. J Urol 1976;116:764.
50. 188Re. Appl Radiat Isot 1996;47:195.
51. Lin W-Y, Lin C-P, Yeh S-J, et al. Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 1997;24:590.
52. Chang YS, Jeong JM, Kim BK, et al. Effect of carrier on labeling and biodistribution of Re-188-hydroxyethylidene diphosphonate. Korean J Nucl Med 2000;34:344.
53. 188Re for bone pain palliation. Appl Radiat Isot 2001;54:435.
54. 188Re-ethylenediamine-N,N, N′,N′-tetrakis(methylene phosphonic acid) as a potential agent for bone pain palliation. Nucl Med Commun 2002;23:75.
55. Palmedo H, Guhlke S, Bender H, et al. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000;27:123.
56. Savio E, Gaudiano J, Robles AM, et al. Re-HEDP: Pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl Med 2001;1:2.
57. 99mTc-DMSA. J Nucl Med 1981;22:69.
58. 99mTc-DMSA in Walker carcinosarcoma 256 bearing Wistar rats. Korean J Nucl Med 1988;22:65.
59. 186Re] rhenium(V) dimercaptosuccinic acid: A possible tumor radiotherapy agent. Appl Radiat Isot 1991;42-167.
60. 188Re-pentavalent rhenium dimercaptosuccinic acid complex. Nucl Med Commun 1993;14:197.
61. 188Re(V)-DMSA for treatment of cancer: Radiolabeling and biodistribution. Korean J Nucl Med 1998;32:81.
62. 186/188Re(V)-DMSA is significantly reduced when reducing agent is changed from stannous ion to metabisulfite. J Label Compounds Radiopharm 2002;45:675.
63. Visser GWM, Gerretsen M, Herscheid JDM, et al. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: A technical protocol. J Nucl Med 1993;34:1953.
64. Gog FB, Visser GWM, Klok R, et al. Monoclonal antibodies labeled with rhenium-188 using the MAG3 chelate: Relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med 1996;37:352.
65. 3 as prosthetic groups for labeling amines and peptides: Approaches with pre- and postconjugate labeling. Nucl Med Biol 1998;25:621.
66. Griffiths GL, Goldenberg DM, Knapp FF Jr, et al. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: Labeling and animal biodistribution studies. Cancer Res 1991;51:4594.
67. Rhodes BA, Lambert CR, Marek MJ, et al. Re-188 labelled antibodies. Appl Radiat Isot 1996;47:7-14.
68. Hong MK, Jeong JM, Yeo JS, et al. In vitro properties and biodistribution of Tc-99m and Re-188 labeled monoclonal antibody CEA79.4. Korean J Nucl Med 1998;32:516.
69. Kim BK, Jeong JM, Hong MK, et al. A study of stability of high specific activity rhenium-188 labeled antibody [abstr.]. J Nucl Med 1999;40:316P.
70. 188Re labeled antibody for radioimmunotherapy and effect of stabilizing agents. Korean J Nucl Med 2002;36:195.
71. Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukemia prior to stem cell transplantation. Eur J Nucl Med 2001;28:807.
72. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia for myelodysplastic syndrome: Results of a phase I-II study. Blood 2001;98:565.
73. 188Re-RC-160, a somatostatin analogue. Tumor Targeting 1996;2:49.
74. 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 1996;65:214.
75. Bugaj JE, Friebe M, Cyr JE, et al. Radiotherapeutic efficacy of Re-188-P2045 in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) mouse models by specific SSTR-targefing. In: Nicolini M, Mazzi U, eds. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 6. Padova, Italy: SGE Editorials, 2002:357.
76. 11)CCMSH peptide in a murine melanoma bearing mouse model. In: Nicolini M, Mazzi U, eds. Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 6. Padova, Italy: SGE Editorials, 2002;375.